A third retrospective study of AGR2 as a predictor of disease-free survival reports a significant association of decreased survival and increased tumor AGR2 mRNA expression using qRT-PCR among 78 women with tamoxifen-treated ER+ breast cancer but without adjustment for potential confounders [16]. This evidence concerns the gene AGR2 and breast carcinoma.